Skip to main content

Jean-Pascal
Machiels

Representative of the
Medical Oncology

Brussels, Belgium

Head of Institut Roi Albert II Oncology & Hematology Cancer Center
Head of Department of adult and pediatric Oncology and Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain, Brussels).
Chairman of the EORTC head and neck group.

Training: Johns Hopkins School of Medicine, Baltimore USA (Fellow in Medical Oncology 1998-2000) and Université catholique de Louvain (UCLouvain), Brussels, Belgium (MD: 1993; PhD: 2001).
Main interests: Head and Neck cancer, translational research, and early clinical trials (phase 1).

Publications: more than two hundred papers reporting on clinical trials and translational research

Editor: Section Editor (Head and neck cancer), European Journal of Cancer

  1. van Herpen C, Vander Poorten V, Skalova A, Terhaard C, Maroldi R, van Engen A, Baujat B, Locati LD, Jensen AD, Smeele L, Hardillo J, Martineau VC, Trama A, Kinloch E, Even C, Machiels JP; ESMO Guidelines Committee. Electronic address:  Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment, and follow-up. ESMO Open. 2022 Dec;7(6):100602.
  2. Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J, Smeele L, van Herpen C, Castro A, Machiels JP; ESMO Guidelines Committee. ; EURACAN. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2021 Apr;32(4):452-465.
  3. Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V; EHNS Executive Board. ; ESMO Guidelines Committee. Electronic address: ESTRO Executive Board.  i Squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Nov;31(11):1462-1475.
  4. Galot R, Machiels JH. Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN). Cancer Treat Rev. 2020 Apr;85:101992.
  5. Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, Caballero C, Fortpied C, Bogaerts J, Govaerts AS, Staelens D, Raveloarivahy T, Rodegher L, Laes JF, Saada-Bouzid E, Machiels JP. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. Ann Oncol. 2018 Dec 1;29(12):2313-2327.